MX2015012812A - Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor. - Google Patents

Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor.

Info

Publication number
MX2015012812A
MX2015012812A MX2015012812A MX2015012812A MX2015012812A MX 2015012812 A MX2015012812 A MX 2015012812A MX 2015012812 A MX2015012812 A MX 2015012812A MX 2015012812 A MX2015012812 A MX 2015012812A MX 2015012812 A MX2015012812 A MX 2015012812A
Authority
MX
Mexico
Prior art keywords
antibody composition
composition enriched
predominant
antibody
novel medicaments
Prior art date
Application number
MX2015012812A
Other languages
English (en)
Spanish (es)
Inventor
Guillaume Chevreux
Nicolas Bihoreau
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of MX2015012812A publication Critical patent/MX2015012812A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2015012812A 2013-03-15 2014-03-14 Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor. MX2015012812A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1352360A FR3003171B1 (fr) 2013-03-15 2013-03-15 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
PCT/EP2014/055179 WO2014140322A1 (fr) 2013-03-15 2014-03-14 Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Publications (1)

Publication Number Publication Date
MX2015012812A true MX2015012812A (es) 2016-05-09

Family

ID=48771615

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012812A MX2015012812A (es) 2013-03-15 2014-03-14 Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor.

Country Status (11)

Country Link
US (1) US20160046722A1 (https=)
EP (1) EP2968533A1 (https=)
JP (1) JP2016512216A (https=)
KR (1) KR20150132522A (https=)
CN (1) CN105163758B (https=)
AU (1) AU2014230134A1 (https=)
BR (1) BR112015023209A8 (https=)
CA (1) CA2907358A1 (https=)
FR (1) FR3003171B1 (https=)
MX (1) MX2015012812A (https=)
WO (1) WO2014140322A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2729496B8 (en) 2011-07-06 2017-10-18 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
AU2017261142B2 (en) 2016-05-04 2022-03-10 Delaval Holding Ab A cartridge for a teatcup, and a teatcup
FR3053688A1 (fr) * 2016-07-06 2018-01-12 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Mutants fc a activite fonctionnelle amelioree
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
CN113614107A (zh) 2019-01-23 2021-11-05 Encefa公司 Cd31竞争剂及其用途
BR112021023438A2 (pt) * 2019-05-23 2022-01-11 Regeneron Pharma Caracterização de variantes de carga específica de domínio de anticorpos
CN114829407B (zh) * 2019-09-23 2024-06-21 南开大学 利用哺乳动物展示筛选FcγR特异性结合Fc
WO2023041717A1 (en) 2021-09-16 2023-03-23 Aboleris Pharma Anti-human cd45rc binding domains and uses thereof
CN114236010A (zh) * 2021-12-18 2022-03-25 苏州莱奥生物技术有限公司 一种生物活性药物的药代动力学分析方法
CN115073548A (zh) * 2022-08-01 2022-09-20 上海蓝析生物技术有限公司 一种用于重组蛋白药物电荷异构体制备的缓冲体系

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230769B1 (hu) * 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
CN101928344B (zh) * 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
JP2006524039A (ja) * 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
FR2861078B1 (fr) * 2003-10-16 2007-09-21 Lab Francais Du Fractionnement NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
EP2567976B1 (en) * 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP2729496B8 (en) * 2011-07-06 2017-10-18 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains

Also Published As

Publication number Publication date
EP2968533A1 (fr) 2016-01-20
BR112015023209A8 (pt) 2018-01-23
FR3003171B1 (fr) 2015-04-10
JP2016512216A (ja) 2016-04-25
CA2907358A1 (fr) 2014-09-18
FR3003171A1 (fr) 2014-09-19
WO2014140322A1 (fr) 2014-09-18
US20160046722A1 (en) 2016-02-18
CN105163758B (zh) 2017-11-17
BR112015023209A2 (pt) 2017-07-18
AU2014230134A1 (en) 2015-10-29
CN105163758A (zh) 2015-12-16
KR20150132522A (ko) 2015-11-25

Similar Documents

Publication Publication Date Title
MX2015012812A (es) Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor.
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
MX2020009260A (es) Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenerativos.
EA201690159A1 (ru) Способы и композиции для лечения рака
PH12016500094A1 (en) Autotaxin inhibitors
PH12014502406A1 (en) Anti-il-23p19 antibodies
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
MY195289A (en) Anti IL-36R Antibodies
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
EA201490644A1 (ru) Терапевтические пептиды
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
EP4414376A3 (en) Novel depsipeptide and uses thereof
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
HK1213264A1 (zh) 经取代的苯化合物
BR112014010406A2 (pt) cromatografia de sobrecarga e eluto
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
EA201501123A1 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
AU2018279184A1 (en) Anti-TrkB antibodies
NZ735777A (en) Methods and compositions to inhibit symptoms associated with veisalgia
PH12015500349B1 (en) Scirpusin a and scirpusin b and anti-obesity potential thereof